A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.

Mairah T KhanJoely J Irlam-JonesRonnie Rodrigues PereiraBrian LaneHelen R ValentineKai AragakiLars DyrskjøtDavid J McConkeyPeter J HoskinAnanya ChoudhuryCatharine M L West

Published in: British journal of cancer (2021)

A 14-miRNA hypoxia signature can be used with an mRNA hypoxia signature to identify bladder cancer patients benefitting most from having carbogen and nicotinamide with radiotherapy.

Keyphrases

endothelial cells
ejection fraction
newly diagnosed
early stage
prognostic factors
radiation therapy
stem cells
squamous cell carcinoma
patient reported outcomes
locally advanced
rectal cancer